Oncorus

69 articles about Oncorus

• Oncorus Announces Workforce Reduction Plan

  6/1/2023

  Oncorus, Inc. announced that, in response to challenges associated with raising additional capital and pursuing strategic alternatives to secure additional funding, including current market conditions, the Company’s board of directors has approved a workforce reduction of approximately 55 employees, representing substantially all of Oncorus’ workforce, which is expected to be completed by August 2023.

• Oncorus Reports First Quarter 2023 Financial Results and Provides Business Updates

  5/22/2023

  Oncorus, Inc. (Nasdaq: ONCR), an RNA medicines company focused on developing intravenously administered, self-amplifying RNA to transform outcomes for cancer patients, today reported first quarter financial results and provided an update on its business.

• Oncorus Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates

  3/24/2023

  Oncorus, Inc. today reported fourth quarter and full year 2022 financial results and provided an update on its business.

• Oncorus Announces Research Collaboration with Daewoong Pharmaceutical for the Development of Lipid Nanoparticle Formulations for mRNA Drug Candidates

  1/4/2023

  Oncorus, Inc. and Daewoong Pharmaceutical Co., Ltd. (KRX: 069620), a leading South Korean pharmaceutical company, today announced a research collaboration for the discovery and development of novel lipid nanoparticle (LNP) formulations for mRNA drug candidates.

• Oncorus Announces Portfolio Reprioritization to Focus on IV-Administered, Self-Amplifying RNA Medicines for Patients with Cancer

  11/30/2022

  Oncorus, Inc. (Nasdaq: ONCR), an RNA medicines company focused on developing IV administered, self-amplifying RNA to transform outcomes for cancer patients, today announced that it is reprioritizing its pipeline to focus on its lead viral RNA (vRNA) immunotherapy product candidate, ONCR-021.

• Oncorus to Participate in Upcoming Investor Conferences

  11/23/2022

  Oncorus, Inc.today announced that President and Chief Executive Officer, Theodore (Ted) Ashburn, M.D., Ph.D., will participate in two upcoming investor conferences.

• Oncorus Presents Preclinical Data Supporting ONCR-719, an armed HSV-1 Vector engineered to use the Epidermal Growth Factor Receptor (EGFR/EGFRvIII) for viral entry in Glioblastoma, at the 2022 Society for Neuro-Oncology Annual Meeting

  11/18/2022

  Oncorus, Inc. (Nasdaq: ONCR), a viral immunotherapy company focused on driving innovation to transform outcomes for cancer patients, today announced the presentation of preclinical data for ONCR-719 in a poster at the 2022 Society for Neuro-Oncology (SNO) Annual Meeting, taking place November 17-20, 2022 in Tampa, Florida.

• Oncorus Reports Third Quarter 2022 Financial Results and Provides Business Updates

  11/2/2022

  Oncorus, Inc., a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, reported financial results for the third quarter of 2022 and highlighted recent achievements and developments.

• Oncorus Announces Publication in Nature Communications Highlighting the Development of its Intravenously Administered Synthetic vRNA/LNP Platform for the Treatment of Cancer

  10/7/2022

  Oncorus, Inc. (Nasdaq: ONCR) today announced the publication of preclinical data in Nature Communications highlighting the potential of its synthetic viral RNA (vRNA)/lipid nanoparticle (LNP) platform as a novel approach to treating cancer by enabling repeat intravenous (IV) administration of viral immunotherapy.

• Oncorus Appoints Douglas Fambrough to Board of Directors

  6/23/2022

  Oncorus, Inc. (Nasdaq: ONCR), a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, today announced the appointment of Douglas M. Fambrough, III, Ph.D. to its board of directors.

• Oncorus to Present at the Jefferies Global Healthcare Conference - June 01, 2022

  6/1/2022

  Oncorus, Inc. announced that President and Chief Executive Officer, Theodore Ashburn, M.D., Ph.D., will participate in a fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 8, 2022 at 3:30 p.m. ET in New York, NY.

• Oncorus to Present at the H.C. Wainwright Global Investment Conference

  5/17/2022

  Oncorus, Inc. announced that President and Chief Executive Officer, Theodore Ashburn, M.D., Ph.D., will present an update on the Company’s progress at the H.C. Wainwright Global Investment Conference.

• 

  BioSpace Movers & Shakers: Singular Genomics, Marengo, Ventyx, Caribou and More

  5/13/2022

  Life sciences and biopharma companies strengthen their leadership teams and boards with these Movers & Shakers.

• Oncorus Announces Appointment of Richard Wanstall as Chief Financial Officer

  5/10/2022

  Oncorus, Inc., a viral immunotherapy company focused on driving innovation to transform outcomes for cancer patients, announced the appointment of Richard Wanstall as Chief Financial Officer.

• Oncorus Reports First Quarter 2022 Financial Results and Provides Business Updates

  5/4/2022

  Oncorus, Inc. (Nasdaq: ONCR), a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, today reported first quarter 2022 financial results and highlighted recent achievements and developments.

• Oncorus Announces Debt Capital Facility with K2 HealthVentures with $20 Million Funded at Closing, Relocation of Corporate Headquarters and Extension of Cash Runway

  4/5/2022

  Oncorus, Inc. announced that it has entered into a loan and security agreement with K2 HealthVentures, a healthcare focused specialty finance company.

• Oncorus to Present at the Maxim Group 2022 Virtual Growth Conference

  3/21/2022

  Oncorus, Inc., a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, announced that President and Chief Executive Officer, Theodore Ashburn, M.D., Ph.D., will participate in a fireside chat at the Maxim Group 2022 Virtual Growth Conference on Monday, March 28, 2022 at 12:30 p.m. ET.

• Oncorus to Present at the Oppenheimer 32nd Annual Healthcare Conference

  3/10/2022

  Oncorus, Inc. announced that President and Chief Executive Officer, Theodore Ashburn, M.D., Ph.D., will present at the Oppenheimer 32nd Annual Healthcare Conference on Tuesday, March 15, 2022 at 4:40 p.m. ET.

• Oncorus Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Updates

  3/9/2022

  Oncorus, Inc., a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, reported fourth quarter and full year 2021 financial results and highlighted recent achievements and developments.

• Oncorus Announces Promotion of John Goldberg, M.D. to Chief Medical Officer

  2/22/2022

  Oncorus, Inc., a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, announced the promotion of John Goldberg, M.D. to Chief Medical Officer.